Bhutan vs Iraq: Average cost of drugs for extensively drug-resistant tuberculosis
Bhutan
2,259 constant 2022 US$
in 2024
Iraq
2,000 constant 2022 US$
in 2024
Bhutan rank
23rd
Iraq rank
24th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Bhutan
- Iraq
How they compare
Bhutan currently reports 2,259 constant 2022 US$ against 2,000 constant 2022 US$ in Iraq, a difference of 259 constant 2022 US$.
That makes Bhutan's figure about 1.1 times Iraq's.
The two have swapped places 1 time across 6 shared years of data; in 2019 it was Iraq ahead.
Bhutan ranks 23rd and Iraq ranks 24th of 56 countries.
Iraq has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bhutan | Iraq | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,951 constant 2022 US$ | 4,000 constant 2022 US$ | 1,049 constant 2022 US$ | Iraq |
| 2020s | 2,259 constant 2022 US$ | 2,400 constant 2022 US$ | 141 constant 2022 US$ | Iraq |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Bhutan or Iraq?
- Bhutan, at 2,259 constant 2022 US$ against 2,000 constant 2022 US$ in Iraq as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Bhutan and Iraq?
- 259 constant 2022 US$, with Bhutan ahead.
- How many years of comparable data are there for Bhutan and Iraq?
- 6 years are reported by both, from 2019 to 2024.
- How do Bhutan and Iraq rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Bhutan ranks 23rd and Iraq ranks 24th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.